The Prevail DCB is designed to treat narrowed or blocked coronary arteries in patients with coronary artery disease
Medtronic operational headquarters in Fridley, Minnesota, US. (Credit: Group29 at English Wikipedia)
Medical technology company Medtronic has launched next-generation drug coated balloon (DCB) catheter, dubbed Prevail, in Europe.
The Prevail DCB, which has already secured CE mark approval, is indicated for use during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD).
Utilising a rapid absorption drug called paclitaxel, Medtronic’s Prevail DCB facilitates the treatment of de novo lesions, small vessel disease, and in-stent restenosis (ISR).
The Prevail DCB is said to build on the safety and efficacy showed in the earlier generation IN.PACT Falcon DCB clinical programme, as well as reaffirmed by the PREVAIL study.
In the PREVAIL study, the Prevail DCB demonstrated better performance in patients with complex lesions, including those with small vessels and those treated for in-stent restenosis.
Medtronic cardiovascular portfolio’s coronary and renal denervation business president and senior vice president Jason Weidman said: “The launch of the Prevail DCB not only underscores our global leadership and commitment to interventional cardiologists around the world, but also highlights our strong focus on complex PCI.
“We intentionally designed the Prevail DCB to address the challenges posed by smaller, more complex vessels by leveraging our coronary technologies to provide physicians the ability to navigate through tight lesions with greater confidence.”
PowerTrac, the same enhanced technology used in the delivery system of Medtronic’s Resolute Onyx DES, is used in the Prevail DCB.
The technology is said to allow efficient deliverability and two times more pushability than the earlier IN.PACT Falcon technology to facilitate better control for tortuous anatomies.
The Prevail DCB is not yet approved for use in the US.
The DCB catheter is part of the company’s coronary portfolio, which also consists of Resolute Onyx DES in sizes ranging from 2.0-5.0mm, the Euphora semicompliant balloon dilatation catheter, the DxTerity diagnostic angiography catheter line and the Telescope guide extension catheter.